Observational studyAdvances in therapy2025
Real-World Safety and Effectiveness of Vadadustat in Patients with Chronic Kidney Disease-Related Anemia: Interim Analysis of Postmarketing Surveillance in Japan.
Observational study in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Impact of SLCO1B1 Gene Polymorphisms on Vadadustat Pharmacokinetics.European journal of drug metabolism and pharmacokinetics · 2026Observational
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat chronic kidney disease (CKD)-related anemia. This interim analysis presents findings from postmarketing surveillance (PMS) conducted in Japan, assessing the safety and effectiveness of vadadustat in real-world clinical practice.
methodsThis ongoing 2-year observational, multicenter, prospective surveillance collected data from November 2020 to June 2024 to assess adverse drug reactions (ADRs) and hemoglobin (Hb) levels in patients with CKD-related anemia. ADRs of special interest included malignant tumors, thromboembolism, hepatic impairment, hypertension, cardiovascular events excluding thromboembolism, retinal hemorrhage-related ADRs, and the progression of autosomal dominant polycystic kidney disease.
resultsThis interim analysis included 2263 patients enrolled from 420 sites across Japan, with 2191 and 2142 patients analyzed for safety and effectiveness, respectively. The safety analysis population comprised 1429 patients with non-dialysis-dependent (NDD)-CKD, 174 with peritoneal dialysis-dependent (PD)-CKD, and 588 with hemodialysis-dependent (HD)-CKD. The median treatment duration was 365.0 days overall (365.0 days for NDD-CKD and PD-CKD, and 189.0 days for HD-CKD). Treatment with vadadustat was discontinued in approximately half of the patients in each CKD group during the observation period. ADRs and serious ADRs were observed in 14.79% and 6.30% of the patients, respectively. The most common ADRs were nausea (1.19%) and diarrhea (1.14%). ADRs of special interest occurring in more than 1% of patients were malignant tumors (1.14%) and thromboembolism (1.05%). The mean changes in Hb levels from baseline to 12 months in patients who switched from erythropoiesis-stimulating agents (ESAs) to vadadustat and in those without prior ESA use were as follows: 0.30 g/dL and 1.12 g/dL for patients with NDD-CKD; 0.30 g/dL and 0.34 g/dL for PD-CKD; and 0.18 g/dL and 0.90 g/dL for HD-CKD, respectively. Across all CKD subgroups, mean Hb levels increased after treatment with vadadustat in patients with baseline Hb levels < 10 g/dL.
conclusionIn this interim analysis, we identified no new safety concerns beyond those outlined in the Japanese package insert for vadadustat, which is based on the results from pivotal clinical trials. The ongoing PMS will continue to offer valuable insights into the safety and effectiveness of vadadustat in real-world clinical practice.
trial registrationUMIN000042349.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.